Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sartorius AG (GB:0NIR)
LSE:0NIR
Holding GB:0NIR?
Track your performance easily
0NIR Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€200.30 - €383.50
Previous Close€206.54
Volume22.18K
Average Volume (3M)22.32K
Market Cap
€13.09B
Enterprise Value€16.11B
Total Cash (Recent Filing)€196.80M
Total Debt (Recent Filing)€2.54B
Price to Earnings (P/E)172.6
Beta1.81
Next Earnings
Jan 23, 2025EPS Estimate
€1.17Last Dividend Ex-Date
Apr 02, 2024Dividend Yield0.35%
Share Statistics
EPS (TTM)1.21
Shares OutstandingN/A
10 Day Avg. Volume18,366
30 Day Avg. Volume22,322
Standard Deviation0.12
R-Squared0.03
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)3.39
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€254.21Price Target Upside23.08% Upside
Rating ConsensusHold
Number of Analyst Covering15
Sartorius News
PremiumPre-Earnings
Is 0NIR a Buy, Before Earnings?
Bulls Say, Bears Say
Bulls Say
Order Intake GrowthSequential order intake growth of approximately 8% in Bioprocessing is seen as a key positive.
Orderbook PerformanceSartorius delivered a €616m Bioprocessing orderbook, exceeding the €600m consensus.
Performance Against ConsensusThe orderbook was up around 3%, with results bracketed by consensus and analyst numbers in line.
Bears Say
Financial PerformanceEBITDA decreased disproportionately from lower economies of scale.
Market DemandLPS continues to show weak end markets with reluctance for investment from customers, particularly in China.
Revenue GrowthBioprocessing recovery is still slow, indicating challenges in achieving revenue targets.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
15.41% Mutual Funds
<0.01% Other Institutional Investors
71.96% Public Companies and
Individual Investors
0NIR FAQ
What was Sartorius AG’s price range in the past 12 months?
Sartorius AG lowest share price was €200.30 and its highest was €383.50 in the past 12 months.
What is Sartorius AG’s market cap?
Currently, no data Available
When is Sartorius AG’s upcoming earnings report date?
Sartorius AG’s upcoming earnings report date is Jan 23, 2025 which is in 62 days.
How were Sartorius AG’s earnings last quarter?
Sartorius AG released its earnings results on Oct 17, 2024. The company reported €0.87 earnings per share for the quarter, beating the consensus estimate of €0.859 by €0.011.
Is Sartorius AG overvalued?
According to Wall Street analysts Sartorius AG’s price is currently Undervalued.
Does Sartorius AG pay dividends?
Sartorius AG pays a Annually dividend of €0.74 which represents an annual dividend yield of 0.35%. See more information on Sartorius AG dividends here
What is Sartorius AG’s EPS estimate?
Sartorius AG’s EPS estimate is €1.17.
How many shares outstanding does Sartorius AG have?
Sartorius AG has 37,440,000 shares outstanding.
What happened to Sartorius AG’s price movement after its last earnings report?
Sartorius AG reported an EPS of €0.87 in its last earnings report, beating expectations of €0.859. Following the earnings report the stock price went up 14.752%.
Which hedge fund is a major shareholder of Sartorius AG?
Currently, no hedge funds are holding shares in GB:0NIR
---
Sartorius Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€254.21 (23.08% Upside)
€254.21 (23.08% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.63%
12-Months-Change
Fundamentals
Return on Equity
3.51%
Trailing 12-Months
Asset Growth
-1.67%
Trailing 12-Months
Company Description
Sartorius AG
Sartorius AG is the leading provider of biopharmaceutical fermentation and fluid management. In 2019, the bioprocess division contributed 77% to total revenue and the lab division the remaining 23%. The bioprocess division is traded as a separate company, Sartorius Stedim Biotech. Sartorius AG has a 74% ownership of this subsidiary with 85% voting control. In addition to biomanufacturing equipment and consumables, Sartorius offers a wide range of products for general lab use, such as scales, pipettes, and filtration equipment. The business is geographically diverse, with revenue across Europe, the Middle East, and Africa (38% of 2019 sales), the Americas (37%), and Asia-Pacific (25%). Sartorius employs over 9,000 people and has operations in more than 30 countries.
---
0NIR Stock 12 Month Forecast
Average Price Target
€254.21
▲(23.08% Upside)
Technical Analysis
Best Analysts Covering 0NIR
1 Year
1 Year Success Rate
11/36 ratings generated profit
1 Year Average Return
+1.76%
reiterated a buy rating last month
Copying Richard Vosser's trades and holding each position for 1 Year would result in 30.56% of your transactions generating a profit, with an average return of +1.76% per trade.
---